Clinical Trial: Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Recurrent Endometrial Serous Adenocarcinoma
Study Type: INTERVENTIONAL
Official Title: Phase II Trial of Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
Brief Summary:
This phase II trial tests how well niraparib and dostarlimab work in treating patients with uterine serous carcinoma that has come back (after a period of improvement) (recurrent) and remains despite treatment (persistent).Niraparib belongs to a class of drugs called PARP inhibitors that prevent cancer cells from growing.Dostarlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.Dostarlimab belongs to a class of drugs called PD-1 inhibitors that uses the…
Read more